Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

Phyton Biotech Receives CEP for Docetaxel API

Published: Thursday, June 20, 2013
Last Updated: Thursday, June 20, 2013
Bookmark and Share
Helps alleviate docetaxel shortage through plant cell fermentation process.

Phyton Biotech has been granted a Certificate of suitability to European Pharmacopeia (CEP) by the European Directorate for the Quality of Medicines and HealthCare (EDQM) for its docetaxel anhydrous active pharmaceutical ingredient (API).

Phyton is the first North American or European based contract API supplier to be granted a CEP for docetaxel.

Importantly, Phyton’s docetaxel API is not subject to the current worldwide shortage of 10-deacetylbaccatin (10-DAB) starting material because it uses paclitaxel from its own plant cell fermentation facility as its starting material.

Comments CTO and VP, Business Development, Roland Franke, PhD: “Virtually every other docetaxel API supplier in the world uses 10-DAB as their docetaxel starting material. Unfortunately, docetaxel API is now in short supply because we are in one of the periodic shortages of 10-DAB. 10-DAB is derived from yew tree plantations which - as we are seeing again - are subject to climate, environmental, and harvesting issues. Our docetaxel API is different. It uses paclitaxel as its starting material; and the paclitaxel we use is via plant cell fermentation that is produced at our own facility near Hamburg, Germany. Troubling as well, is that 10-DAB is also the starting material for most sources of paclitaxel API so it would not surprise me to see near term and periodic shortages of this API too.”

Adds General Manger, Marc Iacobucci: “Phyton has invested heavily to become the leading supplier of high quality docetaxel and paclitaxel API in the world. Our enormous capacity to produce paclitaxel from plant cell fermentation (which incidentally is nearly 800 kg API annually at the fermentation stage) eliminates reliance on yew tree plantations and their inherent problems related to the environment, sustainability, reliability, and consistent quality. We control the production and quality of our products from starting material to finished API, which few other such suppliers can claim. This CEP follows the CEP we were granted last summer for our plant cell fermentation paclitaxel API. These milestones are especially important to Phyton as the CEP is widely recognized as certification of API quality; and makes it much easier for our customers to gain market authorization to use our API’s both in highly regulated markets and those emerging markets that are placing more emphasis on product quality.”

The CEP procedure assesses and concludes suitability of monographs to control the chemical purity and quality for any substance covered by a European Pharmacopoeia monograph; and checks compliance at the manufacturing and/or distribution site(s) covered by CEPs with both Good Manufacturing Practices for medicinal products and the information submitted in the application.

The CEP, in part, facilitates and simplifies exchanges between regulators and industry to ensure the quality of substances used in the production of pharmaceutical products and that such substances comply with the European Pharmacopoeia; and facilitates the management of marketing authorization applications for medicinal products.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More Than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
High Throughput Mass Spectrometry-Based Screening Assay Trends
Dr John Comley provides an insight into HT MS-based screening with a focus on future user requirements and preferences.
Revolutionary Technologies Developed to Improve Outcomes for Lung Cancer Patients
Breath test to detect lung cancer brings oxygen directly to the wound.
NIH Supports New Studies to Find Alzheimer’s Biomarkers in Down Syndrome
Initiative will track dementia onset, progress in Down syndrome volunteers.
Dementia Linked to Deficient DNA Repair
Mutant forms of breast cancer factor 1 (BRCA1) are associated with breast and ovarian cancers but according to new findings, in the brain the normal BRCA1 gene product may also be linked to Alzheimer’s disease.
Using Drug-Susceptible Parasites to Fight Drug Resistance
Researchers at the University of Georgia have developed a model for evaluating a potential new strategy in the fight against drug-resistant diseases.
Boosting Breast Cancer Treatment
To more efficiently treat breast cancer, scientists have been researching molecules that selectively bind to cancer cells and deliver a substance that can kill the tumor cells, for several years.
New Gene Map Reveals Cancer’s Achilles’ Heel
Team of researchers switches off almost 18,000 genes
New Discovery Sheds Light on Disease Risk
Gaps between genes interact to influence the risk of acquiring disease.
How Cells ‘Climb’ to Build Fruit Fly Tracheas
Mipp1 protein helps cells sprout “fingers” for gripping.
Research Finding Could Lead to Targeted Therapies for IBD
Findings published online in Cell Reports.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos